Detalhe da pesquisa
1.
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Cancer
; 129(17): 2637-2644, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37354090
2.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033
3.
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols.
Blood
; 119(1): 49-54, 2012 Jan 05.
Artigo
Inglês
| MEDLINE | ID: mdl-22049518
4.
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Acta Haematol
; 129(2): 126-34, 2013.
Artigo
Inglês
| MEDLINE | ID: mdl-23207803
5.
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
Haematologica
; 97(4): 560-7, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22102706
6.
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Ann Hematol
; 91(9): 1345-9, 2012 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-22569854
7.
FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis.
Haematologica
; 98(12): e161-3, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24323990
8.
Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine.
Ann Hematol
; 92(3): 411-2, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-23007277
9.
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
Br J Haematol
; 159(5): 612-3, 2012 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-23043319
10.
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.
Haematologica
; 97(2): e2, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22298822
11.
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRß rearrangement and type 1 diabetes.
Ann Hematol
; 91(11): 1823-4, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22623162
12.
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Ann Hematol
; 91(2): 309-10, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-21625998
13.
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Clin Adv Hematol Oncol
; 10(4): 266-8, 2012 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-22706491
14.
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.
Br J Haematol
; 152(1): 119-21, 2011 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-21029071
15.
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica
; 96(10): e41-2, 2011 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-21972212
16.
The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS.
Haematologica
; 96(12): e45, 2011 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22271927
17.
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
Br J Haematol
; 150(2): 240-2, 2010 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-20346015
18.
Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
Acta Oncol
; 49(3): 399-400, 2010 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-20105089
19.
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.
Acta Haematol
; 124(1): 46-8, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20616538
20.
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.
Cancer Lett
; 333(1): 32-5, 2013 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23291359